Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis

British Journal of Dermatology

Volumn 166, Issue 4, 2012, Pages 884-887

  Fernandez Penas P ^a,b   Jones Caballero, M ^a   Espallardo, O ^c   Garcia Diez A ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BODY SURFACE; COMPARATIVE STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS DISABILITY INDEX; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; SKINDEX 29;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; DISABILITY EVALUATION; EMOTIONS; FEMALE; HEALTH STATUS; HUMANS; INTERPERSONAL RELATIONS; LEISURE ACTIVITIES; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84859132409     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10806.x     Document Type: Article

References (14)

1. Schmitt J, Wozel G,. The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210: 194-9.
2. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-5.
3. Both H, Essink-Bot ML, Busschbach J, et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127: 2726-39.
4. De Korte J, Mombers FM, Sprangers MA, et al. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002; 138: 1221-7.
5. Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 17-22.
6. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
7. Nijsten T, Whalley D, Gelfand J, et al. The psychometric properties of the Psoriasis Disability Index in United States patients. J Invest Dermatol 2005; 125: 665-72.
8. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
9. Chren M, Lasek R, Flocke S, et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-40.
10. Jones-Caballero M, Peñas PF, García-Díez A, et al. The Spanish version of Skindex-29. Int J Dermatol 2000; 39: 907-12.
11. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
12. Finlay AY, Khan GK, Luscombe DK, et al. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123: 751-6.
13. Ware J,. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
14. Badia X, Mascaro JM, Lozano R,. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol 1999; 141: 698-702.